Optimization of monoclonal antibody, binding to lymphokine active factor 3 (LAG-3)； two chemical molecules including the factor； immunococcus, including the binding of antibody and therapeutic agent； compound； nucleic acid； vector； ulcer cell； preparation method； inhibition of tumor growth or use of tumor treatment Viral infection
The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.LA INVENCIÓN PROPORCIONA UN ANTICUERPO MONOCLONAL OPTIMIZADO QUE SE UNE AL GEN 3 DE ACTIVACIÓN DE LINFOCITOS (LAG-3)； MOLÉCULA BIESPECÍFICA QUE LO COMPRENDE； INMUNOCONJUGADO QUE COMPRENDE EL ANTICUERPO UNIDO A UN AGENTE TERAPÉUTICO； COMPOSICIÓN； ÁCIDO NUCLEICO； VECTOR； CÉLULA HUÉSPED； MÉTODO DE PREPARACIÓN； Y USO PARA INHIBIR EL CRECIMIENTO DE UN TUMOR O TRATAR UNA INFECCIÓN VIRAL.
